Tripterygium glycosides is proved to not only regulate inflammatory factors such as TNF-α, IL-1β and TGF-β1, but also ameliorate podocyte injury and glomerular hypertrophy, reduce urinary protein in rats with diabetic nephropathy through anti-inflammation and inhibition of macrophage infiltration (Ma et al., 2013; Huang et al., 2020). This evidence concerns the gene TNF and diabetic kidney disease.